Jacob M. Keck

Clinical Pharmacy Specialist, Infectious Diseases and Antimicrobial Stewardship

UAMS

Also affiliated: Baptist Memorial Hospital (2021); Lipscomb University (2019–2021); University of Arkansas Medical Center (2025); University of Mississippi Medical Center (2022)

9 h-index 13 pubs 187 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group

OverviewAI-generated summary

Jacob M. Keck's research focuses on infectious diseases and antimicrobial stewardship, with a particular interest in the treatment of bacterial infections and the mechanisms of antimicrobial resistance. His work includes investigating novel antimicrobial agents, such as cefiderocol, and understanding how bacteria develop resistance to these drugs, specifically in the context of carbapenem-resistant *Acinetobacter baumannii*. Keck also explores broader aspects of infectious disease management, including fever in neutropenic patients and antifungal resistance. His research portfolio extends to the safety and effectiveness of medical interventions, such as delabeling patients with multiple drug allergy labels. Additionally, his work has touched upon the anticancer properties of certain compounds and the role of specific proteins in cellular processes.

Metrics

h-index: 9
Publications: 13
Citations: 187

Positions

Clinical Pharmacy Specialist, Infectious Diseases and Antimicrobial Stewardship 2022–present

University of Arkansas for Medical Sciences Pharmacy ORCID
PGY2 Infectious Diseases Resident 2021–2022

University of Mississippi Medical Center Pharmacy ORCID
PGY1 Pharmacy Resident 2020–2021

Baptist Memorial Hospital Pharmacy ORCID

Selected Publications

Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections (2026)

Antibiotics 1 citation DOI OpenAlex
Use of Aztreonam–Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae (2025)

Antibiotics 2 citations DOI OpenAlex
“Dusting Off the Cobwebs”: Rethinking How We Use New Antibiotics (2025)

Antibiotics 3 citations DOI OpenAlex
It’s Here, It’s There, There’s Fungi Everywhere: A Case Series Utilizing Rezafungin for Invasive Candidiasis (2025)

Infectious Diseases and Therapy 10 citations DOI OpenAlex
New Agents Are Coming, and So Is the Resistance (2024)

Antibiotics 13 citations DOI OpenAlex
Treatment-emergent cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii is associated with insertion sequence IS Aba36 in the siderophore receptor pirA (2024)

Antimicrobial Agents and Chemotherapy 25 citations DOI OpenAlex
Antifungal resistance, combinations and pipeline: oh my! (2023)

Drugs in Context 18 citations DOI OpenAlex
Evaluation of an Antifungal Stewardship Initiative Targeting Micafungin at an Academic Medical Center (2023)

Antibiotics 3 citations DOI OpenAlex